Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug may be used to treat women with ovarian cancer

21.04.2005


A new drug, RAD001, has been shown to stop the growth and movement of certain ovarian cancer cells, according to scientists at Fox Chase Cancer Center in Philadelphia. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, Calif.



A large percentage of human cancers have high activity levels of an enzyme known as AKT. This enzyme controls a number of cell functions, including cell size, division and response to chemotherapy.

"The AKT signaling pathway is overly active in a wide variety of different cancers, including ovarian carcinoma, so we and others think that this pathway is an attractive target for cancer treatment at the molecular level," said Joseph Testa, Ph.D., director of the Human Genetics Program at Fox Chase. "However, because the AKT pathway is involved in so many cell processes, many of them beneficial, we were looking to control some of the proteins downstream from AKT so we didn’t inhibit the good processes."


RAD001 is a derivative of rapamycin, a drug used as an immunosuppressant. RAD001 targets an enzyme known as mTOR (mammalian target of rapamycin). In mice injected with human ovarian cancer cells with high AKT activity, the researchers found that RAD001 arrested the cells so they couldn’t divide (reproduce) or move to another location in the body (metastasize). The drug also reduced the cancer cells’ ability to make blood vessels to nourish themselves (angiogenesis). In cancer cells with low levels of AKT activity, RAD001 had minimal effect.

Testa speculates that after being immobilized by RAD001, ovarian cancer cells could be vulnerable to chemotherapy that would kill the cells while their reproductive properties are weakened.

"Ovarian cancer is the leading cause of gynecologic cancer deaths," Testa said. "It usually isn’t detected until it’s quite advanced and is hard to treat. This is one drug that is well-tolerated and could be useful in ovarian cancer treatment."

Colleen Kirsch | EurekAlert!
Further information:
http://www.fccc.edu

More articles from Life Sciences:

nachricht Topologische Quantenchemie
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

nachricht Topological Quantum Chemistry
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>